Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 54.33 0.56% 0.30
EGRX closed down 0.17 percent on Monday, May 20, 2019, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical EGRX trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.72%
20 DMA Support Bullish 0.72%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.72%
Outside Day Range Expansion 0.72%
Down 3 Days in a Row Weakness 0.72%
Down 4 Days in a Row Weakness 0.72%
MACD Bearish Signal Line Cross Bearish 0.56%
200 DMA Support Bullish 0.56%
20 DMA Support Bullish 0.56%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.56%

Older signals for EGRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Medicine Chemistry Pharmaceutical Organic Chemistry Lymphoma Chronic Lymphocytic Leukemia Lung Cancer Direct Thrombin Inhibitors Heparin Induced Thrombocytopenia Injectable Products Nitrogen Mustards Organochlorides Treatment Of Chronic Lymphocytic Leukemia
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 85.66
52 Week Low 36.03
Average Volume 199,740
200-Day Moving Average 53.8723
50-Day Moving Average 50.6774
20-Day Moving Average 53.81
10-Day Moving Average 55.882
Average True Range 2.3126
ADX 17.36
+DI 25.5671
-DI 21.8452
Chandelier Exit (Long, 3 ATRs ) 52.6372
Chandelier Exit (Short, 3 ATRs ) 53.1878
Upper Bollinger Band 58.8561
Lower Bollinger Band 48.7639
Percent B (%b) 0.51
BandWidth 18.75525
MACD Line 1.4325
MACD Signal Line 1.6454
MACD Histogram -0.2129
Fundamentals Value
Market Cap 818.21 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 9.05
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.90
Resistance 3 (R3) 56.85 55.82 56.40
Resistance 2 (R2) 55.82 55.07 55.84 56.24
Resistance 1 (R1) 54.88 54.60 55.35 54.93 56.07
Pivot Point 53.85 53.85 54.09 53.87 53.85
Support 1 (S1) 52.91 53.10 53.38 52.96 51.81
Support 2 (S2) 51.88 52.63 51.90 51.64
Support 3 (S3) 50.94 51.88 51.48
Support 4 (S4) 50.99